Eli Lilly and Company (NYSE:LLY) PT Raised to $1,001.00 at BMO Capital Markets

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its price target boosted by stock analysts at BMO Capital Markets from $900.00 to $1,001.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an "outperform" rating on the stock. BMO Capital Markets' price target indicates a potential upside of 28.87% from the company's current price.

LLY has been the topic of a number of other reports. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a report on Wednesday, February 7th. Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research note on Tuesday, April 2nd. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. Truist Financial upped their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an "overweight" rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $742.95.

Eli Lilly and Company Stock Down 0.6 %

Shares of LLY traded down $4.35 on Wednesday, reaching $776.75. The company's stock had a trading volume of 2,762,272 shares, compared to its average volume of 3,067,902. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a fifty day moving average of $761.41 and a 200-day moving average of $669.21. The stock has a market capitalization of $738.04 billion, a PE ratio of 133.47, a PEG ratio of 1.61 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $399.26 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business's revenue was up 26.0% on a year-over-year basis. During the same period last year, the business earned $1.62 EPS. Equities analysts predict that Eli Lilly and Company will post 12.51 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lipe & Dalton bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the third quarter worth $27,000. Tidemark LLC bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company's stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Finally, Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth approximately $35,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.